dlt446 dlt446

dlt446 dlt446

Clinical Professor

Member of:

  • Neurology


Publication year:
All
71 - 80 out of 370Page size: 10
Sort by: 1st author
  1. Published

    Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study

    dlt446, dlt446, Tepper, S., Brandes, J. L., Reuter, U., Boudreau, G., Dolezil, D., Cheng, S., Zhang, F., Lenz, R., Klatt, J. & Mikol, D. D., 1 Sep 2018, In: Cephalalgia. 38, 10, p. 1611-1621 11 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  2. Published

    The most important advances in headache research in 2018

    dlt446, dlt446, 2019, In: Lancet Neurology. 18, 1, p. 5-6

    Research output: Contribution to journal › Comment/debate › Research

  3. Published

    Migraine: disease characterisation, biomarkers, and precision medicine

    dlt446, dlt446, Terwindt, G. M., Al-Karagholi, M. A. M., de Boer, I., Lee, M. J., Hay, D. L., Schulte, L. H., Hadjikhani, N., Sinclair, A. J., Ashina, H., Schwedt, T. J. & Goadsby, P. J., 17 Apr 2021, In: The Lancet. 397, 10283, p. 1496-1504 9 p.

    Research output: Contribution to journal › Review › Research › peer-review

  4. Published

    A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine prevention

    dlt446, dlt446, Doležil, D., Bonner, J. H., Zhou, L., Klatt, J., Picard, H. & Mikol, D. D., 2021, In: Cephalalgia. 41, 1, p. 33-44 12 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  5. Published

    Efficacy and safety of eptinezumab in patients with migraine and self-reported aura: Post hoc analysis of PROMISE-1 and PROMISE-2

    dlt446, dlt446, McAllister, P., Cady, R., Hirman, J. & Ettrup, A., 2022, In: Cephalalgia. 42, 8, p. 696-704 9 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  6. Published

    Neurovascular origin of primary headaches

    dlt446, dlt446 & Ayata, C., Apr 2019, In: Journal of Cerebral Blood Flow and Metabolism. 39, 4, p. 571-572

    Research output: Contribution to journal › Editorial › Research › peer-review

  7. Published

    Onset of Efficacy Following Oral Treatment With Lasmiditan for the Acute Treatment of Migraine: Integrated Results From 2 Randomized Double-Blind Placebo-Controlled Phase 3 Clinical Studies

    dlt446, dlt446, Vasudeva, R., Jin, L., Lombard, L., Gray, E., Doty, E. G., Yunes-Medina, L., Kinchen, K. S. & Tassorelli, C., 2019, In: Headache. 59, 10, p. 1788-1801

    Research output: Contribution to journal › Journal article › Research › peer-review

  8. Published

    Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine

    dlt446, dlt446, Goadsby, P. J., Reuter, U., Silberstein, S., Dodick, D., Rippon, G. A., Klatt, J., Xue, F., Chia, V., Zhang, F., Cheng, S. & Mikol, D. D., Oct 2019, In: Cephalalgia. 39, 11, p. 1455-1464

    Research output: Contribution to journal › Journal article › Research › peer-review

  9. Published

    Board Walk – April 2021

    dlt446, dlt446 & Katsarava, Z., 2021, In: Cephalalgia. 41, 5, p. 634-636 3 p.

    Research output: Contribution to journal › Editorial › Research › peer-review

  10. Published

    Pharmacological migraine provocation: a human model of migraine

    dlt446, dlt446 & Hansen, J. M., 1 Jan 2010, In: Handbook of Clinical Neurology. 97, p. 773-9 7 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

Previous 1...4 5 6 7 8 9 10 11 ...37 Next

ID: 920785